« Back to Record
Citation APA

Janssens, A., Berneman, Z. N., Offner, F., Snauwaert, S., Mineur, P., Vanstraelen, G., Meers, S., Spoormans, I., Bron, D., Vande Broek, I., Van Bogaert, C., De Beleyr, B., Smet, A., Nielsen, L., Wapenaar, R., & André, M. (2022). Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) Study. Clinical Hematology International, 4(4), 133-143. doi:10.1007/s44228-022-00020-8


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/370790

Janssens, A., Berneman, Z. N., Offner, F., Snauwaert, S., Mineur, P., Vanstraelen, G., Meers, S., Spoormans, I., Bron, D., Vande Broek, I., Van Bogaert, C., De Beleyr, B., Smet, A., Nielsen, L., Wapenaar, R., & André, M. (2022). Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) Study. Clinical Hematology International, 4(4), 133-143. doi:10.1007/s44228-022-00020-8